Melanoma | Tumor

AU-007 Combo Dosing Begins in Melanoma Phase 2 Trial With Opdivo

April 14th 2025, 4:00pm

Article

AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity and manageable safety.

First Patient Dosed With KSQ-004EX In Solid Tumor Clinical Trial

April 12th 2025, 2:00pm

Article

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.

What Role May ctDNA Have in Melanoma Management?

April 11th 2025, 1:00pm

Article

CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.

Melanoma Taught Me Faith, Gratitude and That Nothing Is Permanent

April 10th 2025, 8:00pm

Article

I was diagnosed with stage 3 melanoma at 31, faced recurrence and now share my journey to raise awareness, stay hopeful and trust in God’s plan.

FDA Grants Breakthrough Therapy to IDE196 in Primary Uveal Melanoma

April 4th 2025, 4:06pm

Article

The FDA granted Breakthrough Therapy designation to IDE196 for the neoadjuvant treatment of primary uveal melanoma when enucleation has been recommended.

First Patient Dosed in Trial of [212Pb]VMT01 for Metastatic Melanoma

March 30th 2025, 6:00pm

Article

The first patient has been dosed with [212Pb]VMT01 in a phase 1/2a trial evaluating the safety of the agent in patients with melanoma.

Solnerstotug Demonstrates Early Efficacy in PD-L1 Resistant Tumors

March 28th 2025, 3:00pm

Article

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.

How Subcutaneous vs IV May Affect Treatment Adherence in Cancer Care

January 27th 2025, 2:00pm

Article

Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version for patients with solid tumors.

The FDA Accepts a BLA for RP1 Plus Opdivo in Advanced Melanoma

January 23rd 2025, 4:00pm

Article

The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have progressed on prior therapy.

The Significance of the Subcutaneous Opdivo FDA Approval in Solid Tumors

January 20th 2025, 2:00pm

Article

Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means for those with solid tumors.